Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 multi-center, randomized, double-masked, placebo-controlled trial of GLK-301 for the treatment of signs and symptoms of Dry Eye Disease (DED)

Next Previous
Trial Profile

Phase 2 multi-center, randomized, double-masked, placebo-controlled trial of GLK-301 for the treatment of signs and symptoms of Dry Eye Disease (DED)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pilocarpine (Primary)
  • Indications Dry eyes
  • Focus First in man; Therapeutic Use

Most Recent Events

  • 10 Jan 2023 According to a Glaukos Corporation media release, the company has announced positive topline results from the trial. Based on the encouraging results, the company plans to advance GLK-301 into a Phase 2b clinical trial targeted to begin in 2023.
  • 18 Jan 2022 New trial record
  • 11 Jan 2022 According to a Glaukos Corporation media release, first patient has been enrolled in this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top